Teladoc Health, Inc.
TDOC
Positions held
Your positionsTDOC isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Teladoc Health operates in a growing telehealth industry, which is expected to expand as more consumers seek convenient healthcare solutions.
- In the most recent quarter, Teladoc's gross margin improved to 68.6%, up from 67.8% in the prior quarter.
- The company's operating margin expanded to -5.7%, indicating a potential for improved profitability moving forward.
- The company's financials show a concerning trend with a negative profit margin of -7.13%, reflecting ongoing challenges in achieving profitability.
- Teladoc's revenue declined by 1% compared to the prior quarter, dropping from $614 million to $607 million.
- The overall score indicates a 'Strong Sell' with a score of -24.00, highlighting significant bearish sentiment among analysts.
Fundamentals
| Market cap | $1.01B | Enterprise value | $1.27B | Trailing P/E | — | Forward P/E | -7.06 |
| PEG | — | Price / book | 0.77 | Beta | 2.14 | Dividend yield | 0.00% |
| Revenue growth | -4.0% | Earnings growth | — | Gross margin | 69.0% | Operating margin | -5.7% |
| Profit margin | -7.1% | ROE | -13.0% | ROA | -3.2% | Debt / equity | 0.79 |
| Current ratio | 0.83 | Free cash flow | $191.04M | Analyst recommendation | hold | Mean target | $7.59 |
| 52w high | $9.89 | 52w low | $4.40 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $607M | $614M | $642M | $626M | $632M |
| Op margin | -5.7% | -7.9% | -4.2% | -5.7% | -7.3% |
| Net income | -$38.9M | -$63.8M | -$25.1M | -$49.5M | -$32.7M |
| Gross margin | 68.6% | 67.8% | 69.3% | 70.1% | 69.8% |
| Gross profit | $416M | $416M | $445M | $439M | $441M |
| Operating income | -$34.5M | -$48.7M | -$27.0M | -$35.5M | -$46.0M |
- Revenue -1% vs prior quarter ($607M vs $614M).
- Gross margin 68.6% (was 67.8% prior quarter).
- Operating margin expanded to -5.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.5B | $2.6B | $2.6B | $2.4B | — |
| Op margin | -6.5% | -8.1% | -8.1% | -9.4% | — |
| Net income | -$200M | -$1.0B | -$220M | -$13.7B | — |
| Gross margin | 69.5% | 70.8% | 70.8% | 69.1% | — |
| Gross profit | $1.8B | $1.8B | $1.8B | $1.7B | — |
| Operating income | -$163M | -$209M | -$211M | -$227M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Teladoc Strengthens Solo Platform With New AI-Powered Care Tools
2026-10-08 · Teladoc Health (TDOC) Could Be 63% Undervalued Following Its New AI Tools
2026-10-07 · Teladoc (TDOC) Sees a More Significant Dip Than Broader Market: Some Facts to Know
2026-10-07 · Teladoc Turns Smartphone Cameras Into AI-Powered Vital Sign Monitors
2026-10-07 · Teladoc Health Launches AI Health Tools for Solo Platform
2026-10-07 · Teladoc unveils remote monitoring, ambient AI features
2026-09-29 · Teladoc (TDOC) Sees a More Significant Dip Than Broader Market: Some Facts to Know
2026-09-29 · Reddit and Teladoc Shares Plummet, What You Need To Know
2026-09-28 · Evergreen Nephrology Appoints Brian Palo as Chief Financial Officer
2026-09-25 · Connected Health & Safety Association Annual Conference Highlights Industry Growth and the Future of Connected Care
2026-09-25 · Teladoc Health Announces Chief Legal Officer Transition
Price (daily)
Full chart · RSI · MACD · patterns